Recent 8-K filings for ENSC
Highest-materiality recent filing
Nasdaq notifies Ensysce of delisting risk for equity shortfall
- Received Nasdaq notice on May 21, 2026 for non-compliance with $2.5M stockholders' equity requirement as of March 31, 2026.
- Must submit a plan by July 6, 2026 (45 days) to regain compliance; if accepted, extension up to 180 days from May 21.
-
Nasdaq notifies Ensysce of delisting risk for equity shortfall
Received Nasdaq notice on May 21, 2026 for non-compliance with $2.5M stockholders' equity requirement as of March 31, 2026.
-
Ensysce Q1 net loss $3.6M; cash $0.7M; Phase 3 trial 50% enrolled; strategic review underway
Net loss attributable to common stockholders $3.6M vs $1.9M in Q1 2025; R&D expense rose to $3.3M on Phase 3 costs.
-
Ensysce closes $2M preferred stock financing from prior $20M commitment; conversion price $0.55
Gross proceeds of $2M from second tranche under November 2025 agreement; net ~$1.9M for TAAP and MPAR programs and working capital.
-
Director Lee Rauch resigns from Ensysce board over severance package dispute
Lee Rauch resigned effective March 24, 2026, citing disagreement with board-approved severance packages.
-
Ensysce Biosciences receives Nasdaq deficiency notice for bid price below $1
Received Nasdaq deficiency letter on Feb 25, 2026; bid price closed below $1 for 30 consecutive business days.
-
Ensysce shareholders approve share issuance to investor and incentive plan increase
Issuance of common stock and warrants to an investor approved: 541,882 for, 195,475 against, 1,030,540 broker non-votes.
-
Ensysce Biosciences closes $4M convertible preferred stock financing with up to $20M available
Closed $4M convertible preferred stock financing; up to $16M additional available in future tranches over 24 months.
-
Ensysce Q3 net loss $3.7M; Phase 3 PF614 trial started; FDA backs PF614-MPAR
Net loss attributable to common stockholders was $3.7M for Q3 2025, vs. a gain of $0.7M in Q3 2024.
-
Ensysce Biosciences reports Q2 2025 net loss of $1.7M, advances Phase 3 trial for PF614
Cash and equivalents $2.2M at June 30, 2025, down from $3.5M at Dec 31, 2024.
-
Net loss of $1.9M vs $3.1M in Q1 2024; R&D spend rose to $1.9M on PF614-MPAR activity.
-
Ensysce raises $2.2M via warrant exercise inducement; issues new warrants for 1.26M shares
Holders exercised 630,376 warrants at $3.24/share for cash; gross proceeds ~$2.2M before fees.
-
Ensysce Biosciences closes $1.1M registered direct offering and private placement of warrants
Gross proceeds of approximately $1.1M from sale of 315,188 shares (or equivalents) at $3.49/share.
-
Ensysce reports Q4 net loss $3.6M, cash $3.5M; signs PF614 commercial launch partner
Cash $3.5M at Dec 2024 vs $4.2M Sept 2024 and $1.1M Dec 2023; 2024 net loss $8.0M vs $10.6M in 2023.
-
Ensysce secures up to $10M R&D funding from Galephar in equity-based development deal
Galephar commits up to $10 million to support R&D, manufacturing, and testing of PF614 and PF614-MPAR.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.65 · Most common event other_material